2023
Ursodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosis
John B, Bastaich D, Webb G, Brevini T, Moon A, Ferreira R, Chin A, Kaplan D, Taddei T, Serper M, Mahmud N, Deng Y, Chao H, Sampaziotis F, Dahman B. Ursodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosis. Journal Of Internal Medicine 2023, 293: 636-647. PMID: 37018129, DOI: 10.1111/joim.13630.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionCritical COVID-19Ursodeoxycholic acidPropensity scoreCOVID-19Severe acute respiratory syndrome coronavirus 2Farnesoid X receptor activityAcute respiratory syndrome coronavirus 2Human lungRespiratory syndrome coronavirus 2COVID-19-related deathsRetrospective cohort studyModerate COVID-19Symptomatic COVID-19Multivariable logistic regressionLarge national cohortSyndrome coronavirus 2Coronavirus disease 2019Angiotensin-converting enzymePotential novel targetUDCA useClinical characteristicsCohort studyVaccination statusCoronavirus 2
2022
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis
John BV, Ferreira RD, Doshi A, Kaplan DE, Taddei TH, Spector SA, Paulus E, Deng Y, Bastaich D, Dahman B. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. Journal Of Hepatology 2022, 77: 1349-1358. PMID: 36181987, PMCID: PMC9519143, DOI: 10.1016/j.jhep.2022.07.036.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesCritical COVID-19COVID-19-related deathsThird doseMRNA vaccinesCOVID-19Propensity-matched control groupRetrospective cohort studyModerate COVID-19Symptomatic COVID-19Veterans Health AdministrationBNT-162b2BNT162b2 mRNAModerna mRNACohort studyImmune dysregulationCirrhosisSimilar riskGeneral populationMagnitude of reductionPatientsControl groupHealth AdministrationVaccineAbstractText